[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 407
Citations 0
Capitol Health Call
March 13, 2013

Letting the Sunshine In

JAMA. 2013;309(10):973. doi:10.1001/jama.2013.1716

Nearly 3 years after passage of the Physician Payments Sunshine Act, the Centers for Medicare & Medicaid Services (CMS) released its final rule intended to increase public awareness of financial relationships between drug and device manufacturers and certain health care practitioners.

The “National Physician Payment Transparency Program: Open Payments” rule, announced February 1, is a part of the Affordable Care Act designed to improve transparency in the health care market. The rule lays out provisions that require manufacturers of drugs, devices, biologicals, and medical supplies covered by Medicare, Medicaid, or the Children's Health Insurance Program to report to CMS any payments or other transfers of value made to physicians and hospitals.

First Page Preview View Large
First page PDF preview
First page PDF preview